Research Article| Volume 43, ISSUE 12, P2366-2373, December 2017

An analysis of factors affecting the accuracy of endoscopic biopsy after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma

Published:October 16, 2017DOI:



      The accuracy of endoscopic esophageal biopsy after neoadjuvant chemoradiotherapy (nCRT) remains suboptimal. We retrospectively examined the factors that may affect the diagnostic accuracy of post-nCRT endoscopic biopsy in patients with esophageal squamous cell carcinoma (ESCC).

      Materials and methods

      A total of 213 ESCC patients were enrolled. Biopsy findings were cross-checked against the final pathology outcomes (ypT0 versus non-ypT0) to assess their accuracy. The independent predictors of diagnostic accuracy were identified by multivariate logistic regression analysis.


      Post-nCRT endoscopic biopsy results were diagnostically consistent with the final pathology outcomes in 116 (54.5%) patients. Multivariate logistic regression analysis identified a long time interval between the completion of nCRT and the endoscopic examination as the only factor independently associated with a higher diagnostic accuracy. Receiver operating characteristic curve analysis showed that the optimal cutoff value for the time interval between nCRT completion and endoscopic biopsy was 45 days. The estimated diagnostic accuracies of biopsies performed before and after the optimal cutoff time were 49.1% and 72.9%, respectively.


      Endoscopic biopsies performed ≥45 days after nCRT are associated with a higher diagnostic accuracy. This time cutoff may serve as a reference to inform the choice of the optimal treatment strategy following nCRT, especially among complete responders in whom surgery withholding is being considered.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Shapiro J.
        • van Lanschot J.J.B.
        • Hulshof M.
        • van Hagen P.
        • van Berge Henegouwen M.I.
        • Wijnhoven B.P.L.
        • et al.
        Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
        Lancet Oncol. 2015; 16: 1090-1098
        • Sjoquist K.M.
        • Burmeister B.H.
        • Smithers B.M.
        • Zalcberg J.R.
        • Simes R.J.
        • Barbour A.
        • et al.
        Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.
        Lancet Oncol. 2011; 12: 681-692
        • van Hagen P.
        • Hulshof M.C.
        • van Lanschot J.J.
        • Steyerberg E.W.
        • van Berge Henegouwen M.I.
        • Wijnhoven B.P.
        • et al.
        Preoperative chemoradiotherapy for esophageal or junctional cancer.
        N Engl J Med. 2012; 366: 2074-2084
        • Piessen G.
        • Messager M.
        • Mirabel X.
        • Briez N.
        • Robb W.B.
        • Adenis A.
        • et al.
        Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal Cancer? An intention-to-treat case-control study.
        Ann Surg. 2013; 258: 793-800
        • Bedenne L.
        • Vincent J.
        • Jouve J.-L.
        Is surgery always necessary in esophageal cancer?.
        Esophagus. 2011; 8: 3-7
        • Rades D.
        • Schild S.E.
        Is surgery necessary following chemoradiation for patients with locally advanced cancer of the esophagus?.
        Nat Clin Pract Oncol. 2007; 4: 506-507
        • Noordman B.J.
        • Shapiro J.
        • Spaander M.C.
        • Krishnadath K.K.
        • van Laarhoven H.W.
        • van Berge Henegouwen M.I.
        • et al.
        Accuracy of detecting residual disease after CROSS neoadjuvant chemoradiotherapy for esophageal cancer (preSANO trial): rationale and protocol.
        JMIR Res Protoc. 2015; 4: e79
        • Molena D.
        • Sun H.
        • Badr A.
        • Mungo B.
        • Sarkaria I.
        • Adusumilli P.
        • et al.
        Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy.
        Dis Esophagus. 2013;
        • Sarkaria I.S.
        • Rizk N.P.
        • Bains M.S.
        • Tang L.H.
        • Ilson D.H.
        • Minsky B.I.
        • et al.
        Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer.
        Ann Surg. 2009; 249: 764-767
        • Miyata H.
        • Yamasaki M.
        • Takiguchi S.
        • Nakajima K.
        • Fujiwara Y.
        • Konishi K.
        • et al.
        Prognostic value of endoscopic biopsy findings after induction chemoradiotherapy with and without surgery for esophageal cancer.
        Ann Surg. 2011; 253: 279-284
        • Yang Q.
        • Cleary K.
        • Yao J.
        • Swisher S.
        • Roth J.
        • Lynch P.
        • et al.
        Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen.
        Dis Esophagus. 2004; 17: 38-43
        • Rice T.W.
        • Gress D.M.
        • Patil D.T.
        • Hofstetter W.L.
        • Kelsen D.P.
        • Blackstone E.H.
        Cancer of the esophagus and esophagogastric junction-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
        CA Cancer J Clin. 2017; 67: 304-317
        • Mandard A.M.
        • Dalibard F.
        • Mandard J.C.
        • Marnay J.
        • Henry-Amar M.
        • Petiot J.F.
        • et al.
        Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations.
        Cancer. 1994; 73: 2680-2686
        • Vermont J.
        • Bosson J.
        • François P.
        • Robert C.
        • Rueff A.
        • Demongeot J.
        Strategies for graphical threshold determination.
        Comput Methods Programs Biomed. 1991; 35: 141-150
        • Shapiro J.
        • ten Kate F.J.
        • van Hagen P.
        • Biermann K.
        • Wijnhoven B.P.
        • van Lanschot J.J.
        Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
        Ann Surg. 2013; 258 (discussion 88–9): 678-688
        • Chao Y.K.
        • Tsai C.Y.
        • Chang H.K.
        • Tseng C.K.
        • Liu Y.H.
        • Yeh C.J.
        A pathological study of residual cancer in the esophageal wall following neoadjuvant chemoradiotherapy: focus on esophageal squamous cell carcinoma patients with false negative preoperative endoscopic biopsies.
        Ann Surg Oncol. 2015; 22: 3647-3652
        • Shapiro J.
        • van Hagen P.
        • Lingsma H.F.
        • Wijnhoven B.P.L.
        • Biermann K.
        • ten Kate F.J.W.
        • et al.
        Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer.
        Ann Surg. 2014; 260: 807-814
        • Ruol A.
        • Rizzetto C.
        • Castoro C.
        • Cagol M.
        • Alfieri R.
        • Zanchettin G.
        • et al.
        Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome?.
        Ann Surg. 2010; 252: 788-796
        • Altman D.G.
        • Bland J.M.
        Statistics Notes: diagnostic tests 2: predictive values.
        Bmj. 1994; 309: 102
        • van Rossum P.S.
        • van Lier A.L.
        • Lips I.M.
        • Meijer G.J.
        • Reerink O.
        • van Vulpen M.
        • et al.
        Imaging of oesophageal cancer with FDG-PET/CT and MRI.
        Clin Radiol. 2015; 70: 81-95
        • van Rossum P.S.
        • van Lier A.L.
        • van Vulpen M.
        • Reerink O.
        • Lagendijk J.J.
        • Lin S.H.
        • et al.
        Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer.
        Radiother Oncol. 2015; 115: 163-170
        • Chao Y.K.
        • Chen H.S.
        • Wang B.Y.
        • Hsu P.K.
        • Liu C.C.
        • Wu S.C.
        Prognosis of patients with pathologic T0 N+ esophageal squamous cell carcinoma after chemoradiotherapy and surgical resection: results from a nationwide study.
        Ann Thorac Surg. 2016; 101: 1897-1902